Cervarix: Two Years Late, But In for the Duration
This article was originally published in RPM Report
GlaxoSmithKline has encountered numerous hurdles trying to get its HPV vaccine onto the market to compete in the US against Merck’s Gardasil. GSK appears fi nally on the verge of completing the long process. The question for GSK—and the rest of the vaccine business—is whether the company has created the case for a strong product differentiation for Cervarix versus Gardasil. If it has, it will trigger a new era of vaccine marketing and product development.
You may also be interested in...
The positive view of vaccines has eroded over time from miracle of medicine to another highpriced Big Pharma product. With renewed commercial success, vaccines are being greeted with skepticism by several segments of the population including some of the public health establishment that was a pillar to vaccines during the lean years for the industry. It’s time to bridge the vaccines trust gap and here’s how.
GSK's Cervarix HPV vaccine is going to miss another back-to-school vaccination season in the US, giving Merck even more time to cement its lead with Gardasil. The delay surprised Wall Street-but shouldn't have. FDA is exercising caution about the approval of a second HPV vaccine - one containing a new active adjuvant. The final approval will set new standards for the coming wave of adjuvant-enhanced vaccines.
The US vaccine industry is a year away from a wave of new, more effective and longer-lasting adjuvant-enhanced products. The technology promises added protection to patients-and extra proprietary rights to product marketers.